Devotees welcome changes in Black Nazarene feast: prelate

MANILA: The organizers of the Nazareno 2023 or the Feast of the Black Nazarene said devotees are ready for the changes in the observance of the annual religious event.

 

“Ready for the new things, so far so good. As I said, this is a transition period. While we are bringing back the pre-pandemic practices, we are integrating the habits of this pandemic. So far, people have been attending, and the desire to have a celebration is more apparent,” Fr. Earl Valdez, attached priest of the Quiapo Church, said in an interview on the sidelines of Tuesday’s press briefing for feast day preparations.

 

Valdez said many people still join the celebration even if some traditional activities remain suspended.

 

“Not to mention, it is not just centered in Quiapo Church but in other parts of the country,” he said.

 

Manila Mayor Honey Lacuna, meanwhile, called on devotees, especially those who will attend feast day activities, such as the Walk of Faith, to wear masks.

 

“We are asking the public to wear masks, especially in crowded areas, practice social distancing and always use alcohol to disinfect,” she said.

 

The Walk of Faith is a procession from the Quirino Grandstand in Luneta Park to Quiapo Church along Quezon Blvd. on Jan. 8, after 12 a.m. Mass.

 

The procession is expected to end after three hours, according to the organizers.

 

The Quiapo Church has decided not to hold the traditional Traslacion or the procession of the Black Nazarene image from Luneta to Quiapo Church amid the threat of the coronavirus disease 2019.

 

The procession was last held in January 2020 and lasted for 16 hours

 

Source: Philippines News Agency

Doctors in France extend strike for another week

ANKARA: Doctors in France have extended their strike for higher pay and working conditions for another week.

 

The strike will continue through the week from Jan. 2 to Jan. 8, with a protest march to be organized in Paris this Thursday, the Medecins Pour Demain (Doctors for Tomorrow) collective said in a statement.

 

The decision was taken because the government failed to address the demands put forward by general practitioners (GPs), the group said on Monday, the day the strike was initially due to end.

 

The collective kicked off the strike on Dec. 26, calling for the basic consultation fees of GPs to be doubled from the current €25 ($26) to €50 ($53), as well as improvements in their overall working conditions.

 

“On the contrary, we were even unfairly criticized by our minister,” the statement said.

 

It was referring to Health Minister Francois Braun’s comments last week, who condemned doctors for protesting “at a time of extreme difficulty” as France struggles with a surge in cases of bronchiolitis, flu, and Covid-19.

 

Source: Philippines News Agency

Minovia Therapeutics to Present at Biotech Showcase on Tuesday, January 10, 2023

Company to be in San Francisco January 8-12, 2023, during 41st Annual J.P. Morgan Health Care Conference

WOBURN, Mass. and HAIFA, Israel, Jan. 03, 2023 (GLOBE NEWSWIRE) — Minovia Therapeutics, a clinical-stage global biotechnology company, today announced that the Company will be presenting at the Biotech Showcase on Tuesday, January 10, 2023, at the Hilton San Francisco Union Square Hotel in San Francisco, CA.

Time: 9:45 AM PST

Track: Franciscan C (Ballroom Level)

Biotech Showcase is an investor conference featuring insights from top investors and biopharma executives.

Interested parties can register to attend the event here:

https://informaconnect.com/biotech-showcase/registration-options/

Additionally, CEO Natalie Yivgi-Ohana and CBO Shai Melcer will be in San Francisco from January 8-12, 2023, during the 41st Annual J.P. Morgan Health Care Conference and will be available for meetings with investors.

Individuals interested in meeting with CEO Natalie Yivgi-Ohana and CBO Shai Melcer can contact shai.melcer@minoviatx.com

About Minovia
Minovia Therapeutics is a clinical-stage global biotechnology company committed to the discovery and development of novel approaches to treating diseases caused by mitochondrial dysfunction. Minovia’s Mitochondrial Augmentation Technology (MAT) platform is designed to extend and enhance human lives by restoring mitochondrial function using autologous stem cells enriched with healthy, functional mitochondria. This unique approach capitalizes on the natural ability of mitochondria to transfer between cells. The company’s initial clinical focus is on primary mitochondrial diseases, such as Pearson syndrome, a fatal pediatric disease, and hematological disorders that include mitochondrial dysfunction.

Findings on safety and efficacy of MAT, both pre-clinical and clinical, may be found in these publications:

https://www.nature.com/articles/s41536-021-00167-7

https://www.science.org/doi/10.1126/scitranslmed.abo3724

Minovia was founded by leading researchers in mitochondrial biology and is headquartered in Haifa, Israel, with operations in Massachusetts.

For more information, visit http://minoviatx.com/.

Contact Information

Shai Melcer, CBO

3 HaSadna st., Tirat Carmel

Israel

Shai.melcer@minoviatx.com

+972-747033354

GlobeNewswire Distribution ID 8722760

Matthews International Wins Over $200 Million in Orders in Fiscal 2023 First Quarter For the Energy Solutions Business

  • Order intake is more than twice fiscal year 2022 revenues for energy storage solutions business
  • Solidifies Matthews International’s position as a leader in the growing electric vehicle (“EV”) energy storage solutions industry
  • Company received orders from multiple manufacturers of EV, battery, and hydrogen fuel cell components

PITTSBURGH, Jan. 02, 2023 (GLOBE NEWSWIRE) — Matthews International Corporation (NASDAQ GSM: MATW) (“Matthews”), a global provider of industrial technologies and renewable energy equipment, today announced that total orders received by the Company during the fiscal 2023 first quarter for its energy storage solutions business exceeded $200 million. The orders have been received from multiple electric vehicle (“EV”), fuel cell, and battery manufacturers to provide equipment and services to the fast-growing business.

“We are very pleased to see continued strength in orders for our energy storage solutions. This order rate reflects industry interest in the proprietary nature of our unique solutions,” said Joseph Bartolacci, President and CEO of Matthews. “Over the past two fiscal years, our energy storage solutions business has more than tripled. With these orders, we are potentially on track this fiscal year for another year of very significant growth.”

About Matthews International Corporation

Matthews International Corporation is a global provider of industrial technologies, memorialization products and brand solutions. The Industrial Technologies segment designs, manufactures, services, and distributes high-tech custom energy storage, marking, coding and industrial automation technologies and solutions. The Memorialization segment is a leading provider of memorialization products, including memorials, caskets, cremation-related products, and cremation and incineration equipment, primarily to cemetery and funeral home customers that help families move from grief to remembrance. The SGK Brand Solutions segment is a leading provider of packaging solutions and brand experiences, helping companies simplify their marketing, amplify their brands, and provide value. The Company has approximately 12,000 employees in more than 26 countries on six continents that are committed to delivering the highest quality products and services.

Forward-looking Information

Any forward-looking statements contained in this release are included pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks and uncertainties that may cause the Company’s actual results in future periods to be materially different from management’s expectations. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove correct. Factors that could cause the Company’s results to differ materially from the results discussed in such forward-looking statements principally include changes in domestic or international economic conditions, changes in foreign currency exchange rates, changes in interest rates, changes in the cost of materials used in the manufacture of the Company’s products, changes in mortality and cremation rates, changes in product demand or pricing as a result of consolidation in the industries in which the Company operates, or other factors such as supply chain disruptions, labor shortages or labor cost increases, changes in product demand or pricing as a result of domestic or international competitive pressures, ability to achieve cost-reduction objectives, unknown risks in connection with the Company’s acquisitions, cybersecurity concerns, effectiveness of the Company’s internal controls, compliance with domestic and foreign laws and regulations, technological factors beyond the Company’s control, impact of pandemics or similar outbreaks, or other disruptions to our industries, customers, or supply chains, the impact of global conflicts, such as the current war between Russia and Ukraine, and other factors described in the Company’s Annual Report on Form 10-K and other periodic filings with the U.S. Securities and Exchange Commission.

For Investor Relations:

William D. Wilson
Senior Director, Corporate Development and Investor Relations
412.325.8418

Matthews International Corporation
Corporate Office
Two NorthShore Center
Pittsburgh, PA  15212-5851
Phone: (412) 442-8200

January 2, 2023 Contact: Steven F. Nicola William D. Wilson
Chief Financial Officer Senior Director
and Secretary Corporate Development

GlobeNewswire Distribution ID 8722570